MTOR and primary cutaneous T-cell non-Hodgkin lymphoma: A novel taspine derivate TPD7 was able to bind to the IL-2 receptor in CTCL and therefore suppressed the downstream cascade, including JAK/STAT and PI3K/AKT/mTOR [115] Additionally, another compound ONC201 exerted time-dependent cell survival inhibition in CTCL cell lines and patient-derived primary CD4+ malignant T cells, and the JAK/STAT pathway was downregulated with ONC201 treatment [116].